The Neox® Difference



The Neox portfolio of human amniotic membrane allografts is focused on wounds and driven by patient outcomes.

- Over 40 years of Research and Development
- Over 400 Peer-Reviewed Publications
- Comprehensive Product Offering of Cryopreserved, Hydrated, and Dry Allografts



An Unwavering Commitment

BioStem is committed to delivering best-in-class solutions for advanced Surgical Care and Wound Care through high-quality placental allograft products that help patients improve their lives while inspiring confidence in our clinicians and partners.

Study Summary: Reference #1, Caporusso studied complex wounds with exposed bone, tendon, muscle, and carrying a significantly higher amputation rate (32%-38%) compared to simpler ulcers (3%-4%).

1. Caporusso J, Motley T, Lantis JC II, et al. A multicentre, randomized, controlled clinical trial assessing cryopreserved ultra-thick human amniotic membrane in the treatment of complex diabetic foot ulcers. *Wound Repair Regen.* 2025;33(6):e70110.

2. Tan EK, Cooke M, Mandrycky C, et al. Structural and Biological Comparison of Cryopreserved and Fresh Amniotic Membrane Tissues. *J Biomater Tissue Eng.* 2014;(4):379–388.

3. Caputo WJ, Vaquero C, Monterosa A, Monterosa P, Johnson E, Beggs D, Fahoury GJ. A retrospective study of cryopreserved umbilical cord as an adjunctive therapy to promote the healing of chronic, complex foot ulcers with underlying osteomyelitis. *Wound Repair Regen.* 2016;24(5):885-893.

4. Raphael A. A single centre, retrospective study of cryopreserved umbilical cord/amniotic membrane tissue for the treatment of diabetic foot ulcers. *J Wound Care.* 2016;25(Suppl 7):S10-S17.

5. International Diabetes Federation. *The diabetic foot.* Brussels, Belgium: International Diabetes Federation; 2020. Accessed August 1, 2022.

6. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. *N Engl J Med.* 2017;376:2367–2375.

biostemtechnologies.com

2836 Center Port Circle, Pompano Beach, FL 33064

©2026 BioStem Technologies, Inc.
All rights reserved | MKTG-072

Neox® is a registered trademark of BioStem Technologies®, Inc. All other trademarks used herein are proprietary to their respective owners.

BioStem Technologies®, Inc. products are registered under the regulations of the U.S. Food and Drug Administration (FDA) governing the manufacture and distribution of Human Tissue Products. They are marketed as structural tissue allografts for homologous use and are used by physicians as barriers, wound coverings, conduits, and/or cushions in the treatment of their patients.

BioStem TECHNOLOGIES®

BioStem TECHNOLOGIES®

When Recovery Matters, We Have a Natural Solution

Studies have shown that birth tissue, when used as a wound covering, can reduce the number of applications and treatment days.[1]



Helping You Get Back to Doing What You Love to Do

As part of your wound care treatment, your physician may suggest the use of human birth tissue products. Birth tissue contains a unique combination of natural components that, when applied as a wound covering, supports wound closure and recovery.[1]

Our proprietary tissue preservation process is the only preservation method that produces a product comparable to fresh tissue.[2]

Studies show that Neox® birth tissue allografts can help improve outcomes for patients with complex wounds and other chronic conditions.[1]



What the Power of Neox® Could Mean for You When Used as a Wound Covering

- **Neox cryopreserved Amniotic Membrane (AM) allografts derived from Umbilical Cord (UC) can help improve outcomes for patients with complex wounds and additional medical conditions[1]**
- **Prospective studies have shown that Neox AM allografts derived from UC nearly doubled the healing rate of standard treatments practices (45.2% vs. 26.9%)[1]**
- **Both prospective and retrospective studies have shown that Neox AM/UC allografts achieved complete wound closure with an average of less than two applications (1. Caporusso 1.67, 3. Caputo 1.24 +/-0.44, 4. Raphael 1.68 +/-0.18) [1,3,4]**

Where Does Our Birth Tissue Come From?

The birth tissue used in all BioStem products is obtained through a voluntary donation program from live and healthy births in the United States. All birth mothers are screened to meet all safety guidelines and requirements of the Food & Drug Administration (FDA).



You're Not Alone

Diabetic Foot Ulcers (DFUs) are a common, serious consequence of longstanding and poorly managed diabetes. Of the estimated **537** million people worldwide who have diabetes, **19% to 34%** will develop a DFU in their lifetime.[5,6]

The primary goals in wound care are to achieve wound closure and reduce the time to do so, and lower the risk of further complications.

We are committed to supporting your physician in achieving these goals with the most advanced products **to help in your recovery and give you peace of mind.**